Loading...
Market
Will Rezolute announce a partnership or acquisition related to RZ358 by March 31, 2025?
3
Resolution / Starting Odds
Yes • 50%
No • 50%
Rezolute Inc official press releases or major financial news outlets
Story
FDA Lifts Partial Hold on Rezolute's Phase 3 Treatment for Congenital Hyperinsulinism
Sep 9, 2024, 12:00 PM
Rezolute Inc announced on Monday that the U.S. Food and Drug Administration (FDA) has lifted the partial clinical hold on its experimental treatment, RZ358, for congenital hyperinsulinism. This decision allows the inclusion of U.S. participants in the ongoing Phase 3 study. The treatment aims to address low blood sugar levels associated with the condition.
View original story
Similar markets
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Pharmaceutical company • 25%
Research institution • 25%
Healthcare provider • 25%
No new partnerships • 25%
